Verified factor-similar pair

FDMO vs JMOM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

UMD
Similarity score
93
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • JMOM has the higher backtested relative Sharpe (1.203 vs 1.058).
  • JMOM has the lower published fee (0.12% vs 0.15%).
  • JMOM is cheaper on dividend valuation (127 vs 163, where 100 is each fund's historical median).
  • FDMO has the stronger regression fit (adjusted R-squared 0.964 vs 0.958).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

FDMO

Fidelity Momentum Factor ETF
UMD
Adj. R2
0.964
Rel. Sharpe
1.058
Mkt beta
1.04
AUM
US$785M
MER
0.15%
Valuation
163

JMOM

JPMorgan U.S. Momentum Factor ETF
UMD
Adj. R2
0.958
Rel. Sharpe
1.203
Mkt beta
1.03
AUM
US$2.1B
MER
0.12%
Valuation
127

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
FDMO
-0.03
|t|
-0.7
JMOM
+0.05
|t|
+1.1
diff -0.07
HML
FDMO
-0.05
|t|
-1.6
JMOM
-0.05
|t|
-1.4
diff +0.00
RMW
FDMO
-0.09
|t|
-2.2
JMOM
-0.06
|t|
-1.3
diff -0.03
CMA
FDMO
-0.02
|t|
-0.4
JMOM
-0.03
|t|
-0.5
diff +0.01
UMD
FDMO
+0.25
|t|
+9.7
JMOM
+0.21
|t|
+7.0
diff +0.04

Why This Pair Matches

Exposure level
92
Exposure shape
97
Mkt beta diff
0.01
Rel. Sharpe diff
0.145

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

FDMO fund page JMOM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.